The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency

BACKGROUND: Patients with primary humoral immunodeficiency are more prone to invasive as well as recurrent pneumococcal infections. Therefore, anti-pneumococcal vaccination including the 13-valent conjugate vaccine is recommended. Nevertheless, to date, no data is available on immunogenicity of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Robbins, Ailsa, Bahuaud, Mathilde, Hentzien, Maxime, Maestraggi, Quentin, Barbe, Coralie, Giusti, Delphine, Le Naour, Richard, Batteux, Frederic, Servettaz, Amélie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287634/
https://www.ncbi.nlm.nih.gov/pubmed/34290713
http://dx.doi.org/10.3389/fimmu.2021.697128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287634/
https://www.ncbi.nlm.nih.gov/pubmed/34290713
http://dx.doi.org/10.3389/fimmu.2021.697128

Ejemplares similares